ATE317844T1 - Adenosine a2a receptor antagonisten - Google Patents

Adenosine a2a receptor antagonisten

Info

Publication number
ATE317844T1
ATE317844T1 AT02784641T AT02784641T ATE317844T1 AT E317844 T1 ATE317844 T1 AT E317844T1 AT 02784641 T AT02784641 T AT 02784641T AT 02784641 T AT02784641 T AT 02784641T AT E317844 T1 ATE317844 T1 AT E317844T1
Authority
AT
Austria
Prior art keywords
adenosine
receptor antagonists
antagonists
receptor
Prior art date
Application number
AT02784641T
Other languages
German (de)
English (en)
Inventor
Julius J Matasi
John P Caldwell
Deen Tulshian
Lisa S Silverman
Bernard R Neustadt
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Application granted granted Critical
Publication of ATE317844T1 publication Critical patent/ATE317844T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Neurosurgery (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
AT02784641T 2001-11-30 2002-11-26 Adenosine a2a receptor antagonisten ATE317844T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US33429301P 2001-11-30 2001-11-30

Publications (1)

Publication Number Publication Date
ATE317844T1 true ATE317844T1 (de) 2006-03-15

Family

ID=23306533

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02784641T ATE317844T1 (de) 2001-11-30 2002-11-26 Adenosine a2a receptor antagonisten

Country Status (18)

Country Link
US (1) US7041666B2 (enExample)
EP (1) EP1453835B1 (enExample)
JP (2) JP4284181B2 (enExample)
KR (1) KR20050044607A (enExample)
CN (1) CN1596258A (enExample)
AR (1) AR038366A1 (enExample)
AT (1) ATE317844T1 (enExample)
AU (1) AU2002346572A1 (enExample)
CA (1) CA2468681C (enExample)
DE (1) DE60209251T2 (enExample)
ES (1) ES2258164T3 (enExample)
HU (1) HUP0402270A3 (enExample)
IL (1) IL161572A0 (enExample)
MX (1) MXPA04005156A (enExample)
PE (1) PE20030739A1 (enExample)
TW (1) TW200300686A (enExample)
WO (1) WO2003048164A2 (enExample)
ZA (1) ZA200404160B (enExample)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1544200A1 (en) * 2002-09-24 2005-06-22 Kyowa Hakko Kogyo Co., Ltd. 1,2,4 -TRIAZOLO 1,5-c PYRIMIDINE DERIVATIVE
US20060106040A1 (en) 2002-12-19 2006-05-18 Michael Grzelak Adenosine A2a receptor antagonists for the treatment of extra-pyramidal syndrome and other movement disorders
CN101310724A (zh) 2002-12-19 2008-11-26 先灵公司 腺苷A2a受体拮抗剂的应用
US20070010522A1 (en) * 2003-04-09 2007-01-11 Chi Vu Triazolo[1,5-c]pyrimidines and pyrazolo[1,5-c]pyrimidines useful as a2a adenosine receptor antagonists
CA2541989C (en) * 2003-10-24 2013-10-01 Exelixis, Inc. P70s6 kinase modulators and method of use
AR050926A1 (es) * 2004-09-03 2006-12-06 Astrazeneca Ab Derivados de benzamida como inhibidores de la histonadesacetilasa(hdac)
WO2006129626A1 (ja) * 2005-05-30 2006-12-07 Kyowa Hakko Kogyo Co., Ltd. [1,2,4]トリアゾロ[1,5-c]ピリミジン誘導体の製造法
ES2273599B1 (es) 2005-10-14 2008-06-01 Universidad De Barcelona Compuestos para el tratamiento de la fibrilacion auricular.
US8835631B2 (en) * 2007-05-24 2014-09-16 Mitsubishi Tanabe Pharma Corporation Therapeutic agent for cerebral infarction
CA2690748A1 (en) * 2007-06-25 2008-12-31 Neurogen Corporation Piperazinyl oxoalkyl tetrahydro-beta-carbolines and related analogues
US20100093764A1 (en) * 2008-10-13 2010-04-15 Devraj Chakravarty AMINES AND SULFOXIDES OF THIENO[2,3-d]PYRIMIDINE AND THEIR USE AS ADENOSINE A2a RECEPTOR ANTAGONISTS
US20100093756A1 (en) * 2008-10-13 2010-04-15 Berbay J Kent HETEROARYL SUBSTITUTED THIENO[2,3-d]PYRIMIDINE AND THEIR USE AS ADENOSINE A2a RECEPTOR ANTAGONISTS
WO2010061696A1 (ja) 2008-11-25 2010-06-03 日産自動車株式会社 導電部材及びこれを用いた固体高分子形燃料電池
EP2424840B1 (en) * 2009-04-27 2014-08-06 Boehringer Ingelheim International GmbH Cxcr3 receptor antagonists
WO2011084985A1 (en) 2010-01-07 2011-07-14 Boehringer Ingelheim International Gmbh Cxcr3 receptor antagonists
JP5843869B2 (ja) * 2010-09-24 2016-01-13 アドヴィナス・セラピューティックス・リミテッド アデノシン受容体拮抗薬としての縮合三環化合物
WO2012127472A1 (en) * 2011-03-22 2012-09-27 Mapi Pharma Ltd. Process and intermediates for the preparation of preladenant and related compounds
JP7065113B2 (ja) * 2017-04-07 2022-05-11 南京明徳新薬研発有限公司 Ａ２Ａ受容体阻害剤としての［１，２，４］トリアゾロ［１，５－ｃ］ピリミジン誘導体
CA3092470A1 (en) * 2018-02-27 2019-09-06 Incyte Corporation Imidazopyrimidines and triazolopyrimidines as a2a / a2b inhibitors
CN112105617B (zh) * 2018-04-28 2022-04-05 南京明德新药研发有限公司 一种三唑并嘧啶类化合物的晶型、盐型及其制备方法
JP7391046B2 (ja) * 2018-05-18 2023-12-04 インサイト・コーポレイション Ａ２ａ／ａ２ｂ阻害剤としての縮合ピリミジン誘導体
JP7490631B2 (ja) 2018-07-05 2024-05-27 インサイト・コーポレイション Ａ２ａ／ａ２ｂ阻害剤としての縮合ピラジン誘導体
TWI820209B (zh) 2018-09-12 2023-11-01 大陸商迪哲（江蘇）醫藥股份有限公司 三唑并－嘧啶化合物及其用途
WO2020106560A1 (en) * 2018-11-20 2020-05-28 Merck Sharp & Dohme Corp. Substituted amino triazolopyrimidine and amino triazolopyrazine adenosine receptor antagonists, pharmaceutical compositions and their use
US12466831B2 (en) * 2018-11-20 2025-11-11 Merck Sharp & Dohme Llc Substituted amino triazolopyrimidine and amino triazolopyrazine adenosine receptor antagonists, pharmaceutical compositions and their use
AU2019388872A1 (en) 2018-11-30 2021-05-27 Merck Sharp & Dohme Llc 7-, 8-, and 10-substituted amino triazolo quinazoline derivatives as adenosine receptor antagonists, pharmaceutical compositions and their use
EA202191498A1 (ru) 2018-11-30 2021-08-20 Мерк Шарп энд Доум Корп. 9-замещенные производные аминотриазолохиназолина в качестве антагонистов аденозиновых рецепторов, фармацевтические композиции и их применение
BR112021011948A2 (pt) 2018-12-20 2021-09-08 Incyte Corporation Compostos de imidazopiridazina e imidazopiridina e usos dos mesmos
WO2020128036A1 (en) * 2018-12-21 2020-06-25 Ryvu Therapeutics S.A. Modulators of the adenosine a2a receptor
TWI829857B (zh) 2019-01-29 2024-01-21 美商英塞特公司 作為a2a / a2b抑制劑之吡唑并吡啶及三唑并吡啶

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU622330B2 (en) 1989-06-23 1992-04-02 Takeda Chemical Industries Ltd. Condensed heterocyclic compounds having a nitrogen atom in the bridgehead for use as fungicides
IT1264901B1 (it) 1993-06-29 1996-10-17 Schering Plough S P A Analoghi eterociclici di 1,2,4-triazolo(15-c)pirimidine ad attivita' antagonista per il recettore a2 dell'adenosina
DE69428977T2 (de) 1993-07-27 2002-07-11 Kyowa Hakko Kogyo Co., Ltd. Arzneimittel gegen Parkinsonsche Krankheit
IT1277392B1 (it) 1995-07-28 1997-11-10 Schering Plough S P A Analoghi eterociclici di 1,2,4-triazolo(1,5-c]pirimidine ad attivita' antagonista per il recettore a2a dell'adenosina
AU743910B2 (en) 1997-03-24 2002-02-07 Kyowa Hakko Kirin Co., Ltd. {1,2,4}triazolo{1,5-c}pyrimidine derivatives
IT1291372B1 (it) 1997-05-21 1999-01-07 Schering Plough S P A Uso di analoghi eterociclici di 1,2,4-triazolo (1,5-c) pirimidine per la preparazione di medicamenti utili per il trattamento delle malattie
CN1328560A (zh) 1998-09-22 2001-12-26 协和发酵工业株式会社 [1,2,4]三唑并[1,5－c]嘧啶衍生物
DE60110219T2 (de) 2000-05-26 2006-03-09 Schering Corp. Adenosin a2a rezeptor antagonisten
WO2002079204A1 (en) * 2001-03-28 2002-10-10 Kyowa Hakko Kogyo Co., Ltd. 8-thiazolyl[1,2,4]triazolo[1,5-c]pyrimidine derivative
WO2003048163A1 (en) 2001-11-30 2003-06-12 Schering Corporation [1,2,4]-TRIAZOLE BICYCLIC ADENOSINE A2a RECEPTOR ANTAGONISTS

Also Published As

Publication number Publication date
EP1453835A2 (en) 2004-09-08
WO2003048164A2 (en) 2003-06-12
DE60209251T2 (de) 2006-11-09
ES2258164T3 (es) 2006-08-16
TW200300686A (en) 2003-06-16
KR20050044607A (ko) 2005-05-12
HUP0402270A3 (en) 2008-09-29
IL161572A0 (en) 2004-09-27
CA2468681C (en) 2011-01-25
DE60209251D1 (de) 2006-04-20
CA2468681A1 (en) 2003-06-12
HK1064100A1 (en) 2005-01-21
CN1596258A (zh) 2005-03-16
MXPA04005156A (es) 2004-08-11
PE20030739A1 (es) 2003-08-28
JP2005511698A (ja) 2005-04-28
HUP0402270A2 (hu) 2005-02-28
JP4284181B2 (ja) 2009-06-24
US7041666B2 (en) 2006-05-09
WO2003048164A3 (en) 2003-10-16
EP1453835B1 (en) 2006-02-15
JP2008303217A (ja) 2008-12-18
AU2002346572A1 (en) 2003-06-17
AR038366A1 (es) 2005-01-12
US20030212080A1 (en) 2003-11-13
ZA200404160B (en) 2005-04-08

Similar Documents

Publication Publication Date Title
ATE317844T1 (de) Adenosine a2a receptor antagonisten
DE60110219D1 (de) Adenosin a2a rezeptor antagonisten
DE60234951D1 (de) Adenosin a2a rezeptor antagonisten
HUP0401925A3 (en) A2b adenosine receptor antagonists
PT1192169E (pt) C-pirazoles agonistas do receptor a2a
DE60219196D1 (de) BICYCLISCHE Ä1,2,4ö-TRIAZOL ADENOSIN A2a REZEPTOR ANTAGONISTEN
NO20032277L (no) Aminotiazoler og deres anvendelse som adenosinreseptorantagonister
CY2011002I1 (el) N-πυρραζολικοι αγωνιστες του α2α υποδοχεα
DK1446379T3 (da) Arylanilin-beta2-adrenergiske receptoragonister
NO20024006L (no) Adenosinreseptor modulatorer
HUP0401437A3 (en) Adenosine a3 receptor agonists
TWI365879B (en) A2b adenosine receptor antagonists
ATE432282T1 (de) 2-alkinyl- und 2-alkenyl-pyrazolo-ä4,3-eü -1,2,4- triazolo-ä1,5-cü -pyrimidinadenosin a2a rezeptorantagonisten
NO20020979L (no) Selektive A2B-adenosinreseptorantagonister
ATE394402T1 (de) Kondensierte purinderivate als a1- adenosinrezeptorantagonisten
DE60214408D1 (de) 5-METHOXY-8-ARYL-i1,2,4öTRIAZOLOi1,5-AöPYRIDINE DERIVATIVE ALS ADENOSIN-REZEPTOR ANTAGONISTEN
EE200300335A (et) Histamiiniretseptori antagonistid
EP1636230A4 (en) ADENOSINE A1 RECEPTOR ANTAGONISTS
DE60220713D1 (de) Ribofuranosyluronamid Derivate als Kristall; ein menschlicher Adenosin A2A Rezeptor Agonsit
ATE320254T1 (de) Crf receptor antagonisten
SI1444233T1 (sl) Antagonisti adenozinskega receptorja A2B
EP1295891A4 (en) Nucleoside derivatives
SE0003996D0 (sv) Receptorantagonister

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties